Understanding the role of NLRP3 inflammasome activation in gout flares points to potential of NLRP3 inflammasome inhibitors as new treatment option.
New Editor in Chief Has Expansive Vision for Arthritis & Rheumatology
Incoming Arthritis & Rheumatology Editor-in-Chief Dr. S. Louis Bridges Jr., MD, PhD, discusses his path to rheumatology and outlines his vision for the journal.
Atherosclerosis in Patients with SLE & the Risk of Progression: A 10-Year View
Research from Papazoglou et al. highlights the substantial risk of atherosclerosis progression and incident cardiovascular events in patients with systemic lupus erythematosus, as well as the importance of prolonged remission and the sustained control of cardiovascular risk factors in mitigating these risks over time.
Ethical Concerns in Rheumatology Require Nuance
Patient autonomy in healthcare decisions and physician conflicts of interest are just two areas of ethical concerns that arise frequently in rheumatology. Dr. Kelly Weselman discusses ethical dilemmas and how to address them.
Advocates for Arthritis 2025: By the Numbers
On May 6, more than 100 members of the rheumatology community participated in 118 meetings with lawmakers from 26 states—urging members of Congress to sustain research funding, address cuts and stabilize Medicare reimbursement, enact pharmacy benefit manager (PBM) reforms and protect Medicaid funding. See photos and stories from the event.
ACR Executive Committee Holds Meetings with Heads of FDA, CMS
As in past administrations, members of the Executive Committee scheduled meetings with leaders of the Food & Drug Administration and Centers for Medicare & Medicaid Services to discuss ACR policy priorities and agency agendas.
Georgia Expands Medical Education Funding as SB 130 Becomes Law
The bill also enhances the state’s service cancelable loan program to help address critical shortages in the healthcare workforce. Much of the language draws from model policy previously developed by the ACR.
ACR, Arthritis Foundation Host Congressional Briefing to Champion Rheumatology Research
The May 6 event brought together patients, physicians and advocates to challenge misconceptions and advocate for sustained investment in rheumatology research.
Underwater Biosimilars Coalition Shares Results of Practice Survey with Congressional Leaders
This week, the Coalition sent Congressional leadership a letter detailing the results of a recent survey about how underwater biosimilars are impacting physicians’ ability to provide high-quality care. Almost all of the nearly 200 practices queried reported being underwater on several biosimilars, with rituximab and infliximab biosimilars being the most common.
Lupus Nephritis: A Brief Review
Among patients with systemic lupus erythematosus (SLE), lupus nephritis is one of the more common health problems and a leading cause of mortality. In adults with SLE, as many as five of 10 will develop kidney disease. In children with lupus, eight of 10 will develop kidney disease.1 Lupus nephritis appears to be more prevalent…
- 1
- 2
- 3
- …
- 817
- Next Page »